drug
berdazimer sodium
Marketedupdated 3mo agoby $PTHS Pelthos Therapeutics Inc.
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jan 5, 2029
~2.4 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (14)
- Jul 10, 2035method-of-use (U-3796)US 10322081
- Jul 10, 2035method-of-use (U-3792)US 10736839
- Jul 10, 2035formulationUS 11040006
- Jul 10, 2035formulationUS 11723858
- Nov 22, 2034method-of-use (U-3799)US 10258564
- Feb 28, 2034formulationUS 11285098
- Feb 27, 2034formulationUS 9855211
- Jul 3, 2032formulationUS 10265334
- Jul 3, 2032formulationUS 9289442
- Sep 3, 2031formulationUS 9526738
- Aug 20, 2030formulationUS 103765384.0y
- Aug 20, 2030method-of-use (U-3802)US 97375614.0y
- May 30, 2026compositionUS 8282967
- May 30, 2026compositionUS 8956658
FDA exclusivities (1)
- Jan 5, 2029NCENew Chemical Entity (5y)2.4y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 10m ago
Found something off?
comments(0)
5-min edit window · permanent after that